SCM
ADVM

Sterling Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Sterling Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-374
Closed -$1.63K – 3267
2025
Q1 		$1.63K Sell
374
-333
-47% -$1.5K ﹤0.01% 2665
2024
Q4 		$3.3K Buy
707
+641
+971% +$4.31K ﹤0.01% 2622
2024
Q3 		$463 Buy
+66
New +$479 ﹤0.01% 2910

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sterling Capital Management's ADVM Position: Q2 2025 in Review

Sterling Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 374 shares — an estimated $1.63K sold.

Sterling Capital Management first reported a position in ADVM in Q3 2024 and held it in 3 quarters. The position peaked at $3.3K in Q4 2024. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • Sterling Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 374 Adverum Biotechnologies shares in Q2 2025, an estimated $1.63K.
  • Sterling Capital Management first reported a position in Adverum Biotechnologies in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Adverum Biotechnologies position peaked at $3.3K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.